Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours

Palliative Care: Industry and Academia – Tensions and Opportunities

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers